News

NeuroCog Trials, Inc. announces support for the cognitive outcomes of a new global Phase 3 clinical trial. This study investigates a genetic-based biomarker risk assignment algorithm to predict risk of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) within a five year period.

NeuroCog Trials, Inc. announces that they have begun providing support for the cognitive outcomes of a new global Phase 3 clinical trial. This study investigates a genetic-based biomarker Trial Press Release: NeuroCog Trials, Inc. announces support for the cognitive...

read more

Trial Press Release: NeuroCog Trials, Inc. announces that the MATRICS Consensus Cognitive Battery (MCCB) and the Schizophrenia Cognition Rating Scale (SCoRS) have been chosen as the co-primary outcome measures by a pharmaceutical company to evaluate their novel compound’s pro-cognitive potential among patients with schizophrenia in an international phase 3 program of clinical trials.

NeuroCog Trials, Inc. announces that the MATRICS Consensus Cognitive Battery (MCCB) and the Schizophrenia Cognition Rating Scale (SCoRS) have been chosen as the co-primary outcome measures by a pharmaceutical company to evaluate their novel compound’s pro-cognitive...

read more